Last week, Apotex Australia, an affiliate of the Canadian-based Apotex, Inc., announced a proposed merger of their Australian and New Zealand generic pharmaceutical and over-the-counter (OTC) operations with Arrow Pharmaceutical.
This combined operation aims to offer pharmacists, patients and consumers a diverse range of almost 500 products, and permit the expansion of current product ranges, including OTC and vitamins. In particular, the merger, anticipated for completion in the new financial year, proposes to expand and diversify the current portfolio through investment in complex products in key therapeutic areas of growth for pharmacy (biosimilars, monoclonal antibodies, respiratory and autoimmune therapies).
